| Budget Amount *help |
¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2019: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2017: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Outline of Final Research Achievements |
Metabolome analysis revealed a decrease in ATP level in the kidneys of tofogliflozin-treated mice and an increase in ATP degradation products, including adenosine. Direct injection of adenosine in the renal artery induced activation of HSL in the white and brown adipose tissues. These results indicate that the renal afferent nerves mediate the lipolytic effect of an SGLT2 inhibitor in obese mice. The alterations to the renal energy metabolism can play significant roles in the lipolysis through the renal afferent nerves and body weight reduction by tofogliflozin. An xanthine oxidase inhibitor, febuxostat, which blocks the degradation pathway of adenine nucleotides, promoted ATP recovery and exerted renoprotective effects in the postischemic kidney.
These findings suggest a novel therapeutic approach for the chronic kidney disease through modification of renal metabolism.
|
